Bay 65-1942 free base NEW
| Price | $1520 | $1980 | $2500 |
| Package | 25mg | 50mg | 100mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-07-17 |
Product Details
| Product Name: Bay 65-1942 free base | CAS No.: 600734-02-9 |
| Supply Ability: 10g | Release date: 2025/07/17 |
Product Introduction
Bioactivity
| Name | Bay 65-1942 free base |
| Description | Bay 65-1942 free base is an ATP-competitive and selective inhibitor of IKKβ. |
| In vitro | Administering Bay 65-1942 before ischemia significantly reduces the size of left ventricular infarcts compared to controls given a placebo. This effect is evident at every measured interval, with notable reductions in the infarct-to-area-at-risk (AAR) ratio when Bay 65-1942 is administered before ischemia, at reperfusion, and after 2 hours of reperfusion, showing significant differences when compared with the placebo group (P<0.05 for each comparison). Furthermore, animals pretreated with Bay 65-1942 exhibited substantially lower creatine kinase-MB (CK-MB) levels, indicating less cardiac muscle damage, compared to those not receiving the compound prior to ischemia-reperfusion (IR), highlighting its protective role against heart tissue damage (P<0.05 vs. placebo). |
| In vivo | AZD6244 and BAY 65-1942 demonstrate synergistic inhibition of cell viability at the dose combination (5 μM AZD6244+10 μM BAY 65-1942), which correlates with IC75 (CI?=?0.48±0.01). AZD6244 and BAY 65-1942 treatment induces 2- and 1.3-fold caspase 3/7 activation, respectively, compared to the DMSO-treated cells. Treatment with a combination of AZD6244 plus BAY 65-1942 leads to a 3.2-fold increase in caspase 3/7 activity[2]. Inhibitors of MEK (AZD6244) and IKK (BAY 65-1942) are used at their IC50 concentrations, as determined by a 48 hour MTS assay, which achieve sufficient inhibition of kinase activity. MYL-R cells are treated for 24 hours with AZD6244 (5 μM), BAY 65-1942 (10 μM), or a combination of these inhibitors at the same concentrations. Synergism is also indicated at the IC50 (CI?=?0.56±0.09) and IC90 (CI?=?0.46±0.02) dose combinations reported by the software (CI values are the mean of three independent experiments, ± standard deviation). |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | IκB | IKKβ | IKK | IkB/IKK | IkB | Bay 65-1942 free base | Bay 651942 free base | Bay 65-1942 | Bay 65 1942 free base |
| Inhibitors Related | JTP 0819958 - HOIPIN-1 | Amlexanox | Malachite green oxalate | Rosmarinic acid | BAY 11-7082 | SC-514 | Resveratrol | Bardoxolone Methyl | GSK8612 | BX795 | CCCP | Allicin |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/25KG |
VIP1Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2025-05-16 | |
| $0.00/1kg |
VIP6Y
|
Zison Pharmaceutical (Shandong) Co., Ltd.
|
2024-05-24 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY